Linical Co., Ltd. (JP:2183) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The phase I/II study “Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities” looks at a new targeted drug for hard to treat cancers. It aims to find a safe dose, then test how well it controls RET altered tumors, which could open a new niche in precision oncology.
The trial drug, TAS0953/HM06, is an oral cancer medicine developed by Taiho with Linical as a collaborator. It aims to block RET gene signals that drive tumor growth in some lung and other solid cancers, offering a focused alternative to broad chemo or older multi target drugs.
This is an interventional study with patients assigned to treatment groups in a non random way. The trial starts with rising doses in small groups, then expands at a selected dose, with no placebo or blinding, and the main goal is to treat cancer while tracking safety and tumor response.
The trial was first submitted on 2020 12 04, marking the formal start of the development path regulators will follow. The latest update on 2026 02 28 signals that the protocol and status are current, which is key for investors watching timing for phase transitions and news flow.
The study is still recruiting, so no top line results are out, but a clean safety profile or strong tumor shrinkage could lift sentiment for Taiho and, to a smaller extent, Linical as a contract partner. Investors should also watch peers in the RET inhibitor space, where positive data can tighten competition but also validate the overall market.
The trial remains active and updated, and further details are available on the ClinicalTrials portal.
To learn more about JP:2183’s potential, visit the Linical Co., Ltd. drug pipeline page.